Natus Medical Inc. (NASDAQ:BABY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.
According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
Other equities analysts have also recently issued research reports about the stock. Raymond James Financial Inc. upgraded shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target on the stock in a research report on Tuesday, September 13th. Benchmark Co. initiated coverage on shares of Natus Medical in a research report on Tuesday, October 4th. They set a “buy” rating and a $55.00 price target on the stock.
Natus Medical (NASDAQ:BABY) traded down 1.41% during midday trading on Monday, reaching $42.00. 510,250 shares of the company’s stock traded hands. The firm has a market cap of $1.36 billion, a PE ratio of 34.15 and a beta of 1.16. The firm’s 50-day moving average is $40.74 and its 200 day moving average is $38.82. Natus Medical has a 52-week low of $29.54 and a 52-week high of $51.05.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, October 19th. The company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.05. Natus Medical had a net margin of 10.89% and a return on equity of 13.53%. The firm had revenue of $90.90 million for the quarter, compared to analysts’ expectations of $89.94 million. During the same quarter in the previous year, the company earned $0.39 earnings per share. The company’s revenue for the quarter was down 3.9% compared to the same quarter last year. Equities research analysts expect that Natus Medical will post $1.64 earnings per share for the current fiscal year.
In related news, CFO Jonathan Kennedy sold 30,276 shares of the business’s stock in a transaction dated Tuesday, October 25th. The shares were sold at an average price of $41.40, for a total transaction of $1,253,426.40. Following the sale, the chief financial officer now owns 91,351 shares of the company’s stock, valued at $3,781,931.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James B. Hawkins acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, October 27th. The shares were acquired at an average cost of $38.30 per share, for a total transaction of $383,000.00. Following the purchase, the insider now directly owns 469,725 shares of the company’s stock, valued at $17,990,467.50. The disclosure for this purchase can be found here. Corporate insiders own 4.80% of the company’s stock.
Large investors have recently bought and sold shares of the company. Point72 Asset Management L.P. acquired a new stake in Natus Medical during the second quarter valued at approximately $23,534,000. Fiera Capital Corp acquired a new stake in Natus Medical during the second quarter valued at approximately $14,075,000. Penn Capital Management Co. Inc. acquired a new stake in Natus Medical during the second quarter valued at approximately $9,979,000. SG Capital Management LLC raised its stake in Natus Medical by 88.6% in the second quarter. SG Capital Management LLC now owns 468,518 shares of the company’s stock valued at $17,710,000 after buying an additional 220,097 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its stake in Natus Medical by 9.9% in the second quarter. Neuberger Berman Group LLC now owns 1,572,351 shares of the company’s stock valued at $59,435,000 after buying an additional 141,770 shares during the last quarter. 84.01% of the stock is currently owned by institutional investors and hedge funds.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.